



PTO/SB21 (02-04)

Approved for use through 07-31-2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Application Number	10/643,450
		Filing Date	August 19, 2003
		First Named Inventor	Breier, et al.
		Art Unit	1654
		Examiner Name	Andrew D. Kosar
Total Number of Pages in This Submission	16	Attorney Docket Number	ERNZ-01084US1

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement and PTO Form 1449 <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance communication to Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Copy of cited reference; return receipt post card; Check #1137 for \$180.00
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY OR AGENT	
Firm Or Individual name	D. Benjamin Borson, PhD., Reg. No. 42,349 1320 Willow Pass Rd., #490, Concord, CA 94520 Telephone: (925) 395-2060
Signature	
Date	February 15, 2007

CERTIFICATE OF TRANSMISSION/MAILING		
I hereby certify that this correspondence is being facsimile transmitted to the USPTO VIA FAX NO. (571) 273-8300 or deposited with the United States Postal Service with sufficient postage as U.S. First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.		
Type or printed name	D. Benjamin Borson, Ph.D.	
Signature		Date February 15, 2007

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEEDS OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patent, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and selection option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: **Breier, et al.**

Examiner: **Andrew D. Kosar**

Serial No.: **10/643,450**

Group Art Unit: **1654**

Filed: **August 19, 2003**

Confirmation No.: **4401**

For: **Regulation of Angiotensin II Receptors in Mammals Subject to Fetal Programming**

Attorney Docket No.: **ERNZ-01084US1**

Mail Stop Amendments
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

This Information Disclosure Statement is being filed in connection with the patent application referenced above. The Examiner is requested to consider each of the references cited herein and forward an initialed copy of the enclosed PTO Form 1449 to the undersigned representative. This Statement is being filed:

- ☐ Upon filing the application.
- ☐ Within three months from the filing date of this application, which is not a continued prosecution application.
- ☐ Within three months from date of entry of the national stage for this application.
- ☐ Before the mailing date of a first Office action on the merits for this application.
- ☐ Before the mailing date of a first Office action after the filing of a request for continued examination.

☒ Before the mailing date of any of: (i) a Final Office Action, (ii) a Notice of Allowance, and (iii) any other action that closes prosecution of this application. The Statement is accompanied by:

- ☐ A Statement pursuant to 37 C.F.R. §1.97(e) or
- ☒ The fee set forth in 37 C.F.R. §1.17(p), believed to be \$180.00.
- ☐ Before payment of the Issue Fee. The Statement is accompanied by:
- ☐ A Statement pursuant to 37 C.F.R. §1.97(e) and
- ☐ The fee set forth in 37 C.F.R. §1.17(p), believed to be _____.

I. Provision of Copies

☒ A copy of each of the references listed on the attached Form PTO Form 1449 is enclosed herewith and forms a part hereof.

☐ A translation of References AA, AB and AC are enclosed herewith and form a part hereof.

☐ A copy of the European Search Report from a corresponding or related EPO application is enclosed herewith.

☐ A copy of the International Search Report from a corresponding or related PCT application is enclosed herewith.

☐ This application claims priority, pursuant to 35 U.S.C. §120, to prior U.S. Application No. _____, filed _____. References not submitted herewith were submitted to or cited by the Office in the prior application(s).

II. Fee

☐ No fee is believed due in connection with filing of this Statement. However, in the event a fee or refund is due, the Commissioner is authorized to charge any fee associated with this communication or credit any overpayment to Deposit Account No. 50-4089.

☐ The fee in the amount \$_____ that is due in connection of filing of this Statement was paid upon electronic filing of a corresponding Statement, which was made on _____ using the ePAVE software.


☒ The fee set forth in 37 C.F.R. §1.17(p), believed to be \$180.00, is believed to be due in connection of filing of this Statement.

☒ Check No. 1137, in the amount \$180.00, is enclosed.

☒ The Commissioner is authorized to charge any other fee associated with this communication, or credit any overpayment, to Deposit Account No. 50-4089.

Respectfully submitted,

Dated: Feb. 15, 2007


D. Benjamin Borson, Ph.D.
Registration No. 42,349
Attorney for Applicant(s)

BORSON LAW GROUP, PC
1320 Willow Pass Road, Suite 490
Concord, California 94520
Tel: (925) 395-2060
Fax: (925) 395-2061



PTO/SB/08B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/643,450		
		Filing Date	August 19, 2003		
		First Named Inventor	Breier, et al.		
		Art Unit	1654		
		Examiner Name	Andrew D. Kosar		
Sheet	1	of	1	Attorney Docket Number	ERNZ-01084US1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	ANNAROSA LERI, "Overexpression of Insulin-Like Growth Factor-1 Attenuates the Myocyte Renin-Angiotensin System in Transgenic Mice", Dept. of Medicine, New York Medical College	
	1	1/18/1999, American Heart Association, Inc., pp. 752-762.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.